These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 22894572)

  • 21. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).
    Roobol MJ; Kerkhof M; Schröder FH; Cuzick J; Sasieni P; Hakama M; Stenman UH; Ciatto S; Nelen V; Kwiatkowski M; Lujan M; Lilja H; Zappa M; Denis L; Recker F; Berenguer A; Ruutu M; Kujala P; Bangma CH; Aus G; Tammela TL; Villers A; Rebillard X; Moss SM; de Koning HJ; Hugosson J; Auvinen A
    Eur Urol; 2009 Oct; 56(4):584-91. PubMed ID: 19660851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening and prostate-cancer mortality in a randomized European study.
    Schröder FH; Hugosson J; Roobol MJ; Tammela TL; Ciatto S; Nelen V; Kwiatkowski M; Lujan M; Lilja H; Zappa M; Denis LJ; Recker F; Berenguer A; Määttänen L; Bangma CH; Aus G; Villers A; Rebillard X; van der Kwast T; Blijenberg BG; Moss SM; de Koning HJ; Auvinen A;
    N Engl J Med; 2009 Mar; 360(13):1320-8. PubMed ID: 19297566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contamination in control group led to no effect of PSA-based screening on prostate cancer mortality at 9 years follow-up: Results of the French section of European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Villers A; Bessaoud F; Trétarre B; Grosclaude P; Malavaud B; Rebillard X; Iborra F; Daubisse L; Malavaud S; Roobol M; Heijnsdijk EA; de Koning HJ; Hugosson J; Rischmann P; Soulié M
    Prog Urol; 2020 Apr; 30(5):252-260. PubMed ID: 32197936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam.
    Wever EM; Draisma G; Heijnsdijk EA; Roobol MJ; Boer R; Otto SJ; de Koning HJ
    J Natl Cancer Inst; 2010 Mar; 102(5):352-5. PubMed ID: 20142584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.
    van Leeuwen PJ; Connolly D; Gavin A; Roobol MJ; Black A; Bangma CH; Schröder FH
    Eur J Cancer; 2010 Jan; 46(2):377-83. PubMed ID: 19804966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening.
    Auvinen A; Moss SM; Tammela TL; Taari K; Roobol MJ; Schröder FH; Bangma CH; Carlsson S; Aus G; Zappa M; Puliti D; Denis LJ; Nelen V; Kwiatkowski M; Randazzo M; Paez A; Lujan M; Hugosson J
    Clin Cancer Res; 2016 Jan; 22(1):243-9. PubMed ID: 26289069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Screening for prostate cancer (PC)--an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Urol Oncol; 2008; 26(5):533-41. PubMed ID: 18774469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
    JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.
    Carlsson S; Assel M; Ulmert D; Gerdtsson A; Hugosson J; Vickers A; Lilja H
    Eur Urol; 2017 Jan; 71(1):46-52. PubMed ID: 27084245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer.
    Roobol MJ; Kranse R; Bangma CH; van Leenders AG; Blijenberg BG; van Schaik RH; Kirkels WJ; Otto SJ; van der Kwast TH; de Koning HJ; Schröder FH;
    Eur Urol; 2013 Oct; 64(4):530-9. PubMed ID: 23759326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lifetime Benefits and Harms of Prostate-Specific Antigen-Based Risk-Stratified Screening for Prostate Cancer.
    Heijnsdijk EAM; Gulati R; Tsodikov A; Lange JM; Mariotto AB; Vickers AJ; Carlsson SV; Etzioni R
    J Natl Cancer Inst; 2020 Oct; 112(10):1013-1020. PubMed ID: 32067047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Summary statement on screening for prostate cancer in Europe.
    Heijnsdijk EAM; Bangma CH; Borràs JM; de Carvalho TM; Castells X; Eklund M; Espinàs JA; Graefen M; Grönberg H; Lansdorp-Vogelaar I; Leeuwen PJV; Nelen V; Recker F; Roobol MJ; Vandenbulcke P; de Koning HJ
    Int J Cancer; 2018 Feb; 142(4):741-746. PubMed ID: 29023685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up.
    Osses DF; Remmers S; Schröder FH; van der Kwast T; Roobol MJ
    Eur Urol; 2019 Mar; 75(3):374-377. PubMed ID: 30420254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
    Schröder FH; Bangma CH; Roobol MJ
    Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts.
    Rove KO; Crawford ED
    World J Urol; 2012 Apr; 30(2):137-42. PubMed ID: 22116599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies.
    Roth JA; Gulati R; Gore JL; Cooperberg MR; Etzioni R
    JAMA Oncol; 2016 Jul; 2(7):890-8. PubMed ID: 27010943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?
    Carlsson SV; Månsson M; Moss S; Kwiatkowski M; Recker F; Tammela TLJ; Bangma C; Roobol MJ; Auvinen A; Hugosson J
    Eur Urol; 2019 Jun; 75(6):1015-1022. PubMed ID: 30928162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH; Hugosson J; Carlsson S; Tammela T; Määttänen L; Auvinen A; Kwiatkowski M; Recker F; Roobol MJ
    Eur Urol; 2012 Nov; 62(5):745-52. PubMed ID: 22704366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.
    Hugosson J; Roobol MJ; Månsson M; Tammela TLJ; Zappa M; Nelen V; Kwiatkowski M; Lujan M; Carlsson SV; Talala KM; Lilja H; Denis LJ; Recker F; Paez A; Puliti D; Villers A; Rebillard X; Kilpeläinen TP; Stenman UH; Godtman RA; Stinesen Kollberg K; Moss SM; Kujala P; Taari K; Huber A; van der Kwast T; Heijnsdijk EA; Bangma C; De Koning HJ; Schröder FH; Auvinen A;
    Eur Urol; 2019 Jul; 76(1):43-51. PubMed ID: 30824296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. To screen or nor to screen: the prostate cancer dilemma.
    Stone NN; Crawford ED
    Asian J Androl; 2015; 17(1):44-5. PubMed ID: 25337849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.